Questions about this study?
The HopeStage team will email you.
TerminatedNCT00554385
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Researchers are studying ABT-089 to find out how it affects ADHD symptoms in children with ADHD.
Medication studyAges 6–12United States
Understand this study
What is this study about?
Researchers are studying ABT-089 to find out how it affects ADHD symptoms in children with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNovember 2007
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 283
- Sponsor
- Abbott
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00554385
- Official title
Show the full official title
The Long-term Safety and Tolerability of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study
Recruitment & locations
TerminatedLittle Rock · Boulder · Bradenton
19 more locations
- Jacksonville
- Orlando
- Libertyville
- Northbrook
- Overland Park
- Troy
- Omaha
- Las Vegas
- Clementon
- Oklahoma City
- Eugene
- Portland
- Salem
- Charleston
- Memphis
- Austin
- Herndon
- Bellevue
- Middleton
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are studying ABT-089 to find out how it affects ADHD symptoms in children with ADHD.
Who is behind this study?
The study sponsor is Abbott.
Does this study involve medication?
Yes. The study involves medication, including ABT-089.
Who can participate?
This study is for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder